301 related articles for article (PubMed ID: 25239496)
1. Long-term treatment with tenofovir in Asian-American chronic hepatitis B patients is associated with abnormal renal phosphate handling.
Tien C; Xu JJ; Chan LS; Chang M; Lim C; Lee S; Huh B; Shinada S; Bae HS; Fong TL
Dig Dis Sci; 2015 Feb; 60(2):566-72. PubMed ID: 25239496
[TBL] [Abstract][Full Text] [Related]
2. Improvement of bone mineral density and markers of proximal renal tubular function in chronic hepatitis B patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide.
Fong TL; Lee BT; Tien A; Chang M; Lim C; Ahn A; Bae HS
J Viral Hepat; 2019 May; 26(5):561-567. PubMed ID: 30576085
[TBL] [Abstract][Full Text] [Related]
3. Altered Underlying Renal Tubular Function in Patients With Chronic Hepatitis B Receiving Nucleos(t)ide Analogs in a Real-World Setting: The MENTE Study.
Rodríguez-Nóvoa S; García-Samaniego J; Prieto M; Calleja JL; Pascasio JM; Delgado Blanco M; Crespo J; Buti M; Bonet Vidal ML; Arenas Ruiz Tapiador J; Fernández-Rodríguez C; Solá R; Fraga E; González Diéguez L; Núñez O; Praga M; Del Pino-Montes J; Romero-Gómez M; Morillas R; Diago M; Castro Á;
J Clin Gastroenterol; 2016 Oct; 50(9):779-89. PubMed ID: 27332746
[TBL] [Abstract][Full Text] [Related]
4. Renal and bone side effects of long-term use of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide fumarate in patients with Hepatitis B: a network meta-analysis.
Liu Z; Zhao Z; Ma X; Liu S; Xin Y
BMC Gastroenterol; 2023 Nov; 23(1):384. PubMed ID: 37950196
[TBL] [Abstract][Full Text] [Related]
5. Improved bone and renal safety in younger tenofovir disoproxil fumarate experienced chronic hepatitis B patients after switching to tenofovir alafenamide or entecavir.
Da Wang F; Zhou J; Li LQ; Li YJ; Wang ML; Tao YC; Zhang DM; Wang YH; Chen EQ
Ann Hepatol; 2023; 28(5):101119. PubMed ID: 37271480
[TBL] [Abstract][Full Text] [Related]
6. Antiviral therapy and the development of osteopenia/osteoporosis among Asians with chronic hepatitis B.
Wei MT; Le AK; Chang MS; Hsu H; Nguyen P; Zhang JQ; Wong C; Wong C; Cheung R; Nguyen MH
J Med Virol; 2019 Jul; 91(7):1288-1294. PubMed ID: 30776311
[TBL] [Abstract][Full Text] [Related]
7. Monotherapy with tenofovir disoproxil fumarate for adefovir-resistant vs. entecavir-resistant chronic hepatitis B: A 5-year clinical trial.
Lim YS; Gwak GY; Choi J; Lee YS; Byun KS; Kim YJ; Yoo BC; Kwon SY; Lee HC
J Hepatol; 2019 Jul; 71(1):35-44. PubMed ID: 30876946
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B.
Lok AS; Trinh H; Carosi G; Akarca US; Gadano A; Habersetzer F; Sievert W; Wong D; Lovegren M; Cohen D; Llamoso C
Gastroenterology; 2012 Sep; 143(3):619-628.e1. PubMed ID: 22643350
[TBL] [Abstract][Full Text] [Related]
9. A novel evidence of serial changes of bone mineral density in chronic hepatitis B patients treated with entecavir.
Huang PY; Chiu SY; Chang KC; Tseng PL; Yen YH; Tsai MC; Wang JH; Kee KM; Chen CH; Hung CH; Chiu KW; Hu TH
Hepatol Int; 2021 Apr; 15(2):310-317. PubMed ID: 33907949
[TBL] [Abstract][Full Text] [Related]
10. Long-term Nucleotide Analogue Treatment Has Higher Levels of Renal Toxicities than Does Entecavir in Patients with Chronic Hepatitis B.
Cho YY; Chang Y; Nam JY; Cho H; Cho EJ; Lee JH; Yu SJ; Yoon JH; Kim YJ
Gut Liver; 2020 Mar; 14(2):225-231. PubMed ID: 31060115
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and safety of switching to entecavir hepatitis B patients developing kidney dysfunction during tenofovir.
Viganò M; Loglio A; Labanca S; Zaltron S; Castelli F; Andreone P; Messina V; Ganga R; Coppola N; Marrone A; Russello M; Marzano A; Tucci A; Taliani G; Fasano M; Fagiuoli S; Villa E; Bronte F; Santantonio T; Brancaccio G; Occhipinti V; Facchetti F; Grossi G; Rumi M; Lampertico P
Liver Int; 2019 Mar; 39(3):484-493. PubMed ID: 30525275
[TBL] [Abstract][Full Text] [Related]
12. Tenofovir alafenamide as compared to tenofovir disoproxil fumarate in the management of chronic hepatitis B with recent trends in patient demographics.
Hsu YC; Wei MT; Nguyen MH
Expert Rev Gastroenterol Hepatol; 2017 Nov; 11(11):999-1008. PubMed ID: 28965428
[TBL] [Abstract][Full Text] [Related]
13. Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B.
Gara N; Zhao X; Collins MT; Chong WH; Kleiner DE; Jake Liang T; Ghany MG; Hoofnagle JH
Aliment Pharmacol Ther; 2012 Jun; 35(11):1317-25. PubMed ID: 22506503
[TBL] [Abstract][Full Text] [Related]
14. Treatment with tenofovir disoproxil fumarate or entecavir in chronic hepatitis B virus-infected patients with renal impairment: results from a 7-year, multicentre retrospective cohort study.
Lampertico P; Berg T; Buti M; Pathil A; Petersen J; Ryder SD; Zoulim F; Botros I; Flaherty JF; Jump B; Op den Brouw ML; van Troostenburg A; Ramroth H;
Aliment Pharmacol Ther; 2020 Aug; 52(3):500-512. PubMed ID: 32583915
[TBL] [Abstract][Full Text] [Related]
15. Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B.
Papatheodoridis GV; Dalekos GN; Idilman R; Sypsa V; Van Boemmel F; Buti M; Calleja JL; Goulis J; Manolakopoulos S; Loglio A; Papatheodoridi M; Gatselis N; Veelken R; Lopez-Gomez M; Hansen BE; Savvidou S; Kourikou A; Vlachogiannakos J; Galanis K; Yurdaydin C; Esteban R; Janssen HLA; Berg T; Lampertico P
J Hepatol; 2020 Nov; 73(5):1037-1045. PubMed ID: 32553667
[TBL] [Abstract][Full Text] [Related]
16. Treatment Outcome and Renal Safety of 3-Year Tenofovir Disoproxil Fumarate Therapy in Chronic Hepatitis B Patients with Preserved Glomerular Filtration Rate.
Min IS; Lee CH; Shin IS; Lee NE; Son HS; Kim SB; Seo SY; Kim SH; Kim SW; Lee SO; Lee ST; Kim IH
Gut Liver; 2019 Jan; 13(1):93-103. PubMed ID: 30400723
[TBL] [Abstract][Full Text] [Related]
17. Evaluating the renal safety of tenofovir disoproxil fumarate in hepatitis B patients without chronic kidney disease.
Tsai HJ; Chuang YW; Yang SS; Chang YZ; Chang HR; Lee TY
J Viral Hepat; 2021 Nov; 28(11):1579-1586. PubMed ID: 34464999
[TBL] [Abstract][Full Text] [Related]
18. Longitudinal trends in renal function in chronic hepatitis B patients receiving oral antiviral treatment.
Udompap P; Kim D; Ahmed A; Kim WR
Aliment Pharmacol Ther; 2018 Dec; 48(11-12):1282-1289. PubMed ID: 30370967
[TBL] [Abstract][Full Text] [Related]
19. Tenofovir disoproxil fumarate vs adefovir dipivoxil in Chinese patients with chronic hepatitis B after 48 weeks: a randomized controlled trial.
Hou JL; Gao ZL; Xie Q; Zhang JM; Sheng JF; Cheng J; Chen CW; Mao Q; Zhao W; Ren H; Tan DM; Niu JQ; Chen SJ; Pan C; Tang H; Wang H; Mao YM; Jia JD; Ning Q; Xu M; Wu SM; Li J; Zhang XX; Ji Y; Dong J; Li J
J Viral Hepat; 2015 Feb; 22(2):85-93. PubMed ID: 25243325
[TBL] [Abstract][Full Text] [Related]
20. Tenofovir is superior to entecavir for achieving complete viral suppression in HBeAg-positive chronic hepatitis B patients with high HBV DNA.
Gao L; Trinh HN; Li J; Nguyen MH
Aliment Pharmacol Ther; 2014 Mar; 39(6):629-37. PubMed ID: 24467455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]